Shrinking the Diagnostic Odyssey: How Advanced Testing is Expanding the Friedreich’s Ataxia Drug Market
In the realm of rare genetic disorders, a therapeutic drug is only commercially viable if the patients who need it can actually be found. Historically, the journey to a Friedreich’s Ataxia (FA) diagnosis was a grueling, multi-year "diagnostic odyssey." Patients frequently bounced between pediatricians, orthopedic surgeons, and general neurologists, repeatedly misdiagnosed with conditions...
0 Commenti
0 condivisioni
362 Views
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt